Vishal Sikri - President Advanced Diagnostics at NEOGENOMICS INC

Issuer-level insider activity

Identity Names, identifiers, and filing context for this profile. 1 identity field
Entity type
Individual
Source evidence Original filing metadata and source links for verification. 1 source field
Source filing history
Open source filing history

No buys or sells have been reported by Vishal Sikri since 12 Aug 2025

Reported holdings for Vishal Sikri in NEOGENOMICS INC

Form 4 holding President Advanced Diagnostics

NEOGENOMICS INC

Security class
Common Stock
Shares / value
128,921
Estimated value
$1,929,225
Report date
23 Feb 2024
Price
$14.96
Ownership
Direct
Form 4 holding President Advanced Diagnostics

NEOGENOMICS INC

Security class
Performance Stock Unit
Shares / value
25,330
Estimated value
$379,048
Report date
23 Feb 2024
Price
$14.96
Ownership
Direct
Underlying class
Common Stock
Underlying amount
21,204
Form 4 holding President Advanced Diagnostics

NEOGENOMICS INC

Security class
Restricted Stock Unit
Shares / value
25,329
Estimated value
$379,033
Report date
23 Feb 2024
Price
$14.96
Ownership
Direct
Underlying class
Common Stock
Underlying amount
21,204
Form 4 holding President Advanced Diagnostics

NEOGENOMICS INC

Security class
Stock Option (Right to Buy)
Shares / value
42,344
Estimated value
Report date
23 Feb 2024
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount
39,683

Transaction history for Vishal Sikri in NEOGENOMICS INC

Sym Class Transaction % SEC-reported value SEC-reported price Shares Shares after Date Ownership
* marks a reported price that did not pass the local price check.
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .